菜单
Header Title

Header SubTitl. Header SubTitl. Header SubTitl. Header SubTitl. Header SubTitl. Header SubTitl. Header SubTitl. Header SubTitl.

Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.

Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.Right Content 70.

Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.

Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.Left Content 70.

Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.

Right Content 50.Right Content 50.Right Content 50.Right Content 50.Right Content 50.Right Content 50.Right Content 50.Right Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.Left Content 50.

Left Content.Left Content.Left Content.Left Content.Left Content.Left Content.Left Content.Left Content.Left Content.Left Content.

  • Text 1
  • Text 2

Style 2

Style 2 Content 1
Style 2 Content 2
Style 2 Content 3

Style 3

Style Left Content. Style Left Content. Style Left Content. Style Left Content. Style Left Content. Style Left Content. Style Left Content.

 

gfds] gfdgfgf
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
fdfdf6565
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.

 

Case Study: Measuring Dual-Binding, T Cell Activation, Cytokine Release, and Tumor Cell Killing in Bispecific T Cell Engagers

Bispecific T cell engagers require specialized in vitro assays to capture their true mechanism of action. Because they activate T cells through coordinated CD3 and tumor-antigen engagement, simple binding or
cytotoxicity tests are not enough. A dedicated TCE assay framework measures synapse formation, tumor-cell killing, customizable cytokine release profile, T cell activation. As shown below, these assays progress from
basic readouts (cell binding, TDCC) to more advanced functional models, including multiplex cytokine panels, activation/exhaustion markers, etc.

In vitro assays supporting T-cell engager optimization.

 

Case Study: Measuring Dual-Binding, T Cell Activation, Cytokine Release, and Tumor Cell Killing in Bispecific T Cell Engagers

Bispecific T cell engagers require specialized in vitro assays to capture their true mechanism of action. Because they activate T cells through coordinated CD3 and tumor-antigen engagement, simple binding or
cytotoxicity tests are not enough. A dedicated TCE assay framework measures synapse formation, tumor-cell killing, customizable cytokine release profile, T cell activation. As shown below, these assays progress from
basic readouts (cell binding, TDCC) to more advanced functional models, including multiplex cytokine panels, activation/exhaustion markers, etc.

In vitro assays supporting T-cell engager optimization.

 

Case Study: Measuring Dual-Binding, T Cell Activation, Cytokine Release, and Tumor Cell Killing in Bispecific T Cell Engagers

Bispecific T cell engagers require specialized in vitro assays to capture their true mechanism of action. Because they activate T cells through coordinated CD3 and tumor-antigen engagement, simple binding or
cytotoxicity tests are not enough. A dedicated TCE assay framework measures synapse formation, tumor-cell killing, customizable cytokine release profile, T cell activation. As shown below, these assays progress from
basic readouts (cell binding, TDCC) to more advanced functional models, including multiplex cytokine panels, activation/exhaustion markers, etc.

In vitro assays supporting T-cell engager optimization.

vdbfdsgfsgfsgfdsgfd

vdbfdsgfsgfsgfdsgfd

How We Support T Cell Engager Discovery and Engineering

TCE discovery involves several connected steps, including target and antibody selection, format design, expression, screening, and production. Progress at this stage depends on sound molecular design, reliable expression systems, efficient screening, and materials suitable for functional testing and downstream development. With experience in antibody engineering and an understanding of later-stage requirements, we support each step of TCE discovery to help teams advance well-characterized, development-ready candidates.

 

In Vitro Assays
  • MOA-driven TCE assay panels
  • Evaluation of potency, safety, response quality, and durability
  • Advanced functional assay design and development
In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.

How We Support T Cell Engager Discovery and Engineering

TCE discovery involves several connected steps, including target and antibody selection, format design, expression, screening, and production. Progress at this stage depends on sound molecular design, reliable expression systems, efficient screening, and materials suitable for functional testing and downstream development. With experience in antibody engineering and an understanding of later-stage requirements, we support each step of TCE discovery to help teams advance well-characterized, development-ready candidates.

 

Antibody Discovery
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
Antibody Discovery
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
Antibody Discovery
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
Antibody Discovery
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.

test test test test test test

How We Support T Cell Engager Discovery and Engineering

TCE discovery involves several connected steps, including target and antibody selection, format design, expression, screening, and production. Progress at this stage depends on sound molecular design, reliable expression systems, efficient screening, and materials suitable for functional testing and downstream development. With experience in antibody engineering and an understanding of later-stage requirements, we support each step of TCE discovery to help teams advance well-characterized, development-ready candidates.

 

In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.
In Vivo Pharmacology
  • Integrated, fit-for-purpose platforms across species
  • NHP PK/PD/Tox studies within 6-11 weeks
  • Science-driven efficacy models for oncology, immunology, metabolism, etc.

Your Project. Our Expertise.